Instil Bio, Inc.
A clinical-stage biopharmaceutical company developing tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Using proprietary, optimized manufacturing processes at its own manufacturing facilities, the company is working to develop a new class of genetically engineered TIL therapies using its Costimulatory Antigen Receptor (CoStAR) platform, including next-generation TIL-306. Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | Texas |
Employees | 49 |
Founded | 2018 |
Financials | |
|---|---|
Market Capitalization | 82.73M |
Revenue | |
Operating Income | -124.68M |
Operating Margin | |
Net Income | -123.32M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4887 / 5373 |
Sector : Healthcare | 931 / 1144 |
Industry : Biotechnology | 487 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 4210 / 5565 |
Sector : Healthcare | 735 / 1182 |
Industry : Biotechnology | 398 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4885 / 5436 |
Sector : Healthcare | 946 / 1164 |
Industry : Biotechnology | 505 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4446 / 5330 |
Sector : Healthcare | 808 / 1174 |
Industry : Biotechnology | 376 / 667 |